GlassScriptPhysician profile
Evan D Slater
NPI 1992869044
$4,294.37
in general payments reported to CMS, 2019-2025
19 companies · $97.13 in 2025
The $97.13 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,308 · 2020: $395 · 2021: $234 · 2023: $1,260 · 2025: $97.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,260 · Food and Beverage: $97.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,260.00 |
| Food and Beverage | $97.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,260.00 | 2023 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $443.69 | 2019-2020 | |
| Celgene Corporation | $440.28 | 2019 | |
| Beigene USA, INC. | $234.39 | 2021 | |
| Genzyme Corporation | $232.37 | 2019 | |
| Tesaro, INC. | $205.81 | 2019 | |
| Clovis Oncology, INC. | $175.20 | 2019 | |
| Sun Pharmaceutical Industries INC. | $137.62 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $125.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Incyte Corporation | $125.00 | 2019 | |
| Seagen INC. | $122.83 | 2019 | |
| Amgen INC. | $117.08 | 2019 | |
| Array Biopharma INC | $101.72 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $100.07 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.21 | 2019 | |
| Gilead Sciences, INC. | $97.13 | 2025 | Trodelvy |
| Kite Pharma, INC. | $19.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Slater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.